Date published: 2025-11-24

00800 4573 8000

SCBT Portrait Logo
Seach Input

Inhibiteurs HRG-β3

HRG-β3 inhibitors are a class of compounds designed to specifically target and inhibit the activity of HRG-β3, a member of the heregulin family of proteins. HRG-β3 (heregulin-β3) is one of several isoforms of the heregulin protein family that plays a crucial role in various cellular signaling pathways. These inhibitors work by binding to HRG-β3 and preventing its interaction with receptors such as ErbB3 and ErbB4, which are part of the ErbB receptor family. By interfering with HRG-β3's ability to engage with its target receptors, the inhibitors modulate the downstream signaling cascades that are typically triggered by HRG-β3's activity, affecting cellular processes such as growth, differentiation, and intracellular communication.

HRG-β3 inhibitors can vary widely depending on their chemical makeup, but they generally possess moieties that enable selective binding to HRG-β3. These compounds are often designed with high specificity for HRG-β3 to minimize off-target effects on other proteins. The design of HRG-β3 inhibitors is guided by structural biology, which allows for precise interactions at the molecular level, ensuring that the binding affinity is strong enough to effectively block HRG-β3 function. HRG-β3 inhibitors may be synthesized using organic chemistry techniques or discovered through high-throughput screening of chemical libraries. Their development involves fine-tuning molecular features such as hydrophobicity, charge distribution, and molecular size to optimize their performance in biochemical environments.

Nom du produitCAS #Ref. CatalogueQuantitéPrix HTCITATIONS Classement

Telmisartan

144701-48-4sc-204907
sc-204907A
50 mg
100 mg
$71.00
$92.00
8
(1)

L'antagoniste des récepteurs de l'angiotensine II pourrait avoir un impact sur la fonction vasculaire et les voies de signalisation associées.

Losartan

114798-26-4sc-353662
100 mg
$127.00
18
(1)

Autre antagoniste des récepteurs de l'angiotensine II, susceptible d'influer sur la pression artérielle et l'angiogenèse.

Atorvastatin

134523-00-5sc-337542A
sc-337542
50 mg
100 mg
$252.00
$495.00
9
(1)

Inhibe la HMG-CoA réductase, influençant potentiellement les niveaux de cholestérol et la signalisation cellulaire liée à l'inflammation et à l'angiogenèse.

BIBF1120

656247-17-5sc-364433
sc-364433A
5 mg
10 mg
$180.00
$315.00
2
(0)

Inhibe de multiples tyrosines kinases impliquées dans l'angiogenèse, affectant potentiellement les processus dans lesquels HRG-β3 pourrait être impliqué.

Thalidomide

50-35-1sc-201445
sc-201445A
100 mg
500 mg
$109.00
$350.00
8
(0)

Modifie les réponses immunitaires et inhibe l'angiogenèse, ce qui pourrait avoir un impact sur les voies liées à HRG-β3.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Inhibe les kinases RAF et d'autres récepteurs, ce qui pourrait avoir un impact sur la prolifération cellulaire et l'angiogenèse.

Metformin

657-24-9sc-507370
10 mg
$77.00
2
(0)

Active l'AMPK, influençant potentiellement les voies métaboliques et la croissance cellulaire liées à HRG-β3.

Ibrutinib

936563-96-1sc-483194
10 mg
$153.00
5
(0)

Inhibe la tyrosine kinase de Bruton, ce qui pourrait affecter la signalisation des cellules B et les réponses immunitaires.